These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38117497)

  • 21. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.
    Wei J; Choi HK; Dalbeth N; Li X; Li C; Zeng C; Lei G; Zhang Y
    JAMA Netw Open; 2023 Aug; 6(8):e2330885. PubMed ID: 37624597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.
    Alkas J; Bosi A; Sjölander A; Barany P; Elinder CG; Fu EL; Carrero JJ
    J Nephrol; 2023 Apr; 36(3):705-711. PubMed ID: 36459371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
    Ha KH; Kim DJ; Choi YJ
    J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.
    Kim M; Ha KH; Lee J; Park S; Oh KS; Bae DH; Lee JH; Kim SM; Choi WG; Hwang KK; Kim DW; Cho MC; Kim DJ; Bae JW
    Korean Circ J; 2024 May; 54(5):256-267. PubMed ID: 38654455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
    JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
    McCormick N; Yokose C; Wei J; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; Zhang Y; Choi HK
    Ann Intern Med; 2023 Aug; 176(8):1067-1080. PubMed ID: 37487215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
    Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
    Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
    Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
    J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
    Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs.
    Alkabbani W; Gamble JM; Eurich DT; Minhas-Sandhu JK; Shah BR; Alsabbagh MW; Zongo A
    Diabetes Metab; 2022 Mar; 48(2):101305. PubMed ID: 34808344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.